CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma...
Phase 1, Phase 2
Birmingham, Alabama, United States and 9 other locations
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...
Phase 1
Birmingham, Alabama, United States and 13 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
Birmingham, Alabama, United States and 9 other locations
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...
Phase 2
Birmingham, Alabama, United States and 31 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Birmingham, Alabama, United States and 59 other locations
a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...
Phase 1, Phase 2
Birmingham, Alabama, United States and 35 other locations
of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...
Phase 1
Birmingham, Alabama, United States and 15 other locations
of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple...
Phase 2
Birmingham, Alabama, United States and 51 other locations
and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple...
Phase 1
Birmingham, Alabama, United States and 18 other locations
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....
Phase 1
Birmingham, Alabama, United States and 18 other locations
Clinical trials
Research sites
Resources
Legal